175 related articles for article (PubMed ID: 35793834)
1. Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.
Teslenko I; Trudeau J; Luo S; Watson CJW; Chen G; Truica CI; Lazarus P
J Pharmacol Exp Ther; 2022 Sep; 382(3):327-334. PubMed ID: 35793834
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Cytosolic Glutathione
Teslenko I; Watson CJW; Xia Z; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1047-1055. PubMed ID: 34593616
[TBL] [Abstract][Full Text] [Related]
3. Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Luo S; Chen G; Truica CI; Baird CC; Xia Z; Lazarus P
Drug Metab Dispos; 2018 Dec; 46(12):1867-1878. PubMed ID: 30257855
[TBL] [Abstract][Full Text] [Related]
4.
Teslenko I; Watson CJW; Chen G; Lazarus P
Mol Pharmacol; 2022 Aug; 102(5):216-22. PubMed ID: 35953090
[TBL] [Abstract][Full Text] [Related]
5. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17
Peterson A; Xia Z; Chen G; Lazarus P
Pharmacol Res Perspect; 2017 Jun; 5(3):e00314. PubMed ID: 28603633
[TBL] [Abstract][Full Text] [Related]
7. Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
Platt A; Xia Z; Liu Y; Chen G; Lazarus P
Pharmacogenet Genomics; 2016 Aug; 26(8):370-80. PubMed ID: 27111237
[TBL] [Abstract][Full Text] [Related]
8. Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.
Peterson A; Xia Z; Chen G; Lazarus P
Pharmacol Res Perspect; 2017 Jun; 5(3):e00313. PubMed ID: 28603632
[TBL] [Abstract][Full Text] [Related]
9. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.
Sweeney C; Ambrosone CB; Joseph L; Stone A; Hutchins LF; Kadlubar FF; Coles BF
Int J Cancer; 2003 Mar; 103(6):810-4. PubMed ID: 12516103
[TBL] [Abstract][Full Text] [Related]
10. Effects of glutathione S-transferase A1 (GSTA1) genotype and potential modifiers on breast cancer risk.
Ahn J; Gammon MD; Santella RM; Gaudet MM; Britton JA; Teitelbaum SL; Terry MB; Neugut AI; Eng SM; Zhang Y; Garza C; Ambrosone CB
Carcinogenesis; 2006 Sep; 27(9):1876-82. PubMed ID: 16624829
[TBL] [Abstract][Full Text] [Related]
11. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
12. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.
Sun D; Chen G; Dellinger RW; Sharma AK; Lazarus P
Pharmacogenet Genomics; 2010 Oct; 20(10):575-85. PubMed ID: 20697310
[TBL] [Abstract][Full Text] [Related]
13. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
14. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
15. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
Goss PE; Qi S; Josse RG; Pritzker KP; Mendes M; Hu H; Waldman SD; Grynpas MD
Bone; 2004 Mar; 34(3):384-92. PubMed ID: 15003786
[TBL] [Abstract][Full Text] [Related]
16. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
17. Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Amaral C; Augusto TV; Tavares-da-Silva E; Roleira FMF; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2018 Oct; 183():51-61. PubMed ID: 29791862
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2E1, GSTA1 and GSTP1 gene variants on serum alpha glutathione S-transferase level in patients undergoing anaesthesia.
Mikstacki A; Skrzypczak-Zielinska M; Zakerska-Banaszak O; Tamowicz B; Skibinska M; Molinska-Glura M; Szalata M; Slomski R
BMC Med Genet; 2016 May; 17(1):40. PubMed ID: 27179909
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.
Bredschneider M; Klein K; Mürdter TE; Marx C; Eichelbaum M; Nüssler AK; Neuhaus P; Zanger UM; Schwab M
Clin Pharmacol Ther; 2002 Jun; 71(6):479-87. PubMed ID: 12087351
[TBL] [Abstract][Full Text] [Related]
20. Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Chanawong A; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2017 Jun; 361(3):482-491. PubMed ID: 28404691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
